Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (6): 549-557.doi: 10.3969/j.issn.1000-6621.2020.06.004
• Original Articles • Previous Articles Next Articles
XU Yan, LU Xi-wei(), CAI Chun-kui, SUN Shi-xue, GU Xiao-feng, YU Yang, LI Gang, WANG Ying
Received:
2020-04-18
Online:
2020-06-10
Published:
2020-06-11
Contact:
LU Xi-wei
E-mail:yiluxiwei@126.com
XU Yan, LU Xi-wei, CAI Chun-kui, SUN Shi-xue, GU Xiao-feng, YU Yang, LI Gang, WANG Ying. Retrospective study of CT imaging evolution of treatment failure patients with multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(6): 549-557. doi: 10.3969/j.issn.1000-6621.2020.06.004
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.06.004
CT征象 | 治疗前 | 治疗后 | χ2值 | P值 | ||
---|---|---|---|---|---|---|
例数 | 检出率(%) | 例数 | 检出率(%) | |||
树芽征 | 38 | 67.9 | 5 | 8.9 | 41.108 | 0.000 |
磨玻璃状影 | 12 | 21.4 | 1 | 1.8 | 10.530 | 0.001 |
结节状病灶 | 45 | 80.4 | 34 | 60.7 | 5.198 | 0.023 |
实变影 | 45 | 80.4 | 36 | 64.3 | 3.613 | 0.057 |
空洞 | 54 | 96.4 | 48 | 85.7 | 2.783 | 0.094 |
支气管扩张 | 5 | 8.9 | 21 | 37.5 | 12.823 | 0.000 |
支气管壁增厚 | 13 | 23.2 | 18 | 32.1 | 1.115 | 0.291 |
支气管聚拢迂曲 | 12 | 21.4 | 23 | 41.1 | 5.029 | 0.025 |
肺气肿 | 28 | 50.0 | 32 | 57.1 | 0.574 | 0.449 |
空气潴留 | 8 | 14.3 | 16 | 28.6 | 3.394 | 0.065 |
巨大薄壁空洞和囊腔 | 7 | 12.5 | 15 | 26.8 | 3.620 | 0.057 |
钙化 | 6 | 10.7 | 9 | 16.1 | 0.693 | 0.405 |
纤维化 | 3 | 5.4 | 10 | 17.9 | 4.264 | 0.039 |
肺动脉增宽 | 7 | 12.5 | 12 | 21.4 | 1.585 | 0.208 |
毁损肺 | 3 | 5.4 | 13 | 23.2 | 7.292 | 0.007 |
胸膜增厚 | 3 | 5.4 | 4 | 7.1 | 0.249 | 0.618 |
肺不张 | 1 | 1.8 | 5 | 8.9 | 2.818 | 0.093 |
CT征象 病变类别 | 病灶 (处) | 吸收 [处(构成比,%)] | 无明显变化 [处(构成比,%)] | 进展 [处(构成比,%)] |
---|---|---|---|---|
树芽征 | ||||
新增 | 23 | 16(69.6) | 3(13.0) | 4(17.4) |
固有 | 31 | 21(67.7) | 2(6.5) | 8(25.8) |
合计 | 54 | 37(68.5) | 5(9.3) | 12(22.2) |
空洞 | ||||
新增 | 2 | 1(1/2) | 1(1/2) | 0(0.0) |
固有 | 108 | 47(43.5) | 25(23.1) | 36(33.4) |
合计 | 110 | 48(43.6) | 26(23.6) | 36(32.8) |
结节状病灶 | ||||
新增 | 20 | 13(65.0) | 3(15.0) | 4(20.0) |
固有 | 74 | 33(44.6) | 23(31.1) | 18(24.3) |
合计 | 94 | 46(48.9) | 26(27.7) | 22(23.4) |
肺实变 | ||||
新增 | 4 | 4(4/4) | 0(0.0) | 0(0.0) |
固有 | 47 | 28(59.6) | 2(4.3) | 17(36.1) |
合计 | 51 | 32(62.8) | 2(3.9) | 17(33.3) |
复合征象(干酪性肺实变+空洞) | ||||
新增 | 0 | 0(0.0) | 0(0.0) | 0(0.0) |
固有 | 19 | 4(21.1) | 1(5.3) | 14(73.6) |
合计 | 19 | 4(21.1) | 1(5.3) | 14(73.6) |
复合征象(树芽征+肺实变/空洞) | ||||
新增 | 0 | 0(0.0) | 0(0.0) | 0(0.0) |
固有 | 7 | 3(3/7) | 0(0.0) | 4(4/7) |
合计 | 7 | 3(3/7) | 0(0.0) | 4(4/7) |
[1] | 中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073. |
[2] | 周婕, 党丽云, 沈聪 , 等. 耐多药肺结核患者胸部影像学特征分析. 实用放射学杂志, 2018,34(9):1348-1350,1385. |
[3] |
Chuchottaworn C, Thanachartwet V, Sangsayunh P , et al. Risk Factors for Multidrug-Resistant Tuberculosis among Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand. PLoS One, 2015,10(10):e0139986.
doi: 10.1371/journal.pone.0139986 URL |
[4] | 董文波, 马灿光, 王彦辉 . 耐多药与药物敏感肺结核的CT影像学表现. 中国实用医刊, 2017,44(7):77-80. |
[5] | 中国防痨协会. 耐药结核病化学治疗指南(2009). 中国防痨杂志, 2010,32(4):181-198. |
[6] |
Cadosch D, Abel Zur Wiesch P, Kouyos R , et al. The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PLoS Comput Biol, 2016,12(3):e1004749.
doi: 10.1371/journal.pcbi.1004749 URL |
[7] | 张俊仙, 吴雪琼 . 结核分枝杆菌对抗结核药物耐受机制的研究进展. 中国防痨杂志, 2015,37(11):1150-1155. |
[8] | 李玲, 姚嵩, 邹铮 , 等. 全球基金结核病项目安徽省试点耐多药结核病综合防治效果分析. 中国防痨杂志, 2017,39(7):728-731. |
[9] | 徐彩红, 张慧, 阮云洲 , 等. 我国六省(自治区)全球基金项目地区耐多药肺结核诊疗效果的回顾性分析. 中国防痨杂志, 2018,40(6):559-563. |
[10] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[11] | Yi L, Yoshiyama T, Okumura M , et al. Linezolid as a Potentially Effective Drug for the Treatment of Multidrug-Resistant Tuberculosis in Japan. Jpn J Infect Dis, 2017,70(1):96-99. |
[12] | Lange C, Dheda K, Chesov D , et al. Management of drug-resistant tuberculosis. Lancet, 2019,394(10202):953-966. |
[13] | Wang Q, Pang Y, Jing W , et al. Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China. Antimicrob Agents Chemother, 2018,62(4):e02149-17. |
[14] | Wáng YXJ, Chung MJ, Skrahin A , et al. Radiological signs associated with pulmonary multi-drug resistant tuberculosis:an analysis of published evidences. Quant Imaging Med Surg, 2018,8(2):161-173. |
[15] | Li D, He W, Chen B , et al. Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findings. PLoS One, 2017,12(6):e0176354. |
[16] | Song Q, Zhang G, Jiang H , et al. Imaging Features of Pulmonary CT in Type 2 Diabetic Patients with Multidrug-Resistant Tuberculosis. PLoS One, 2016,11(3):e0152507. |
[17] | Chakaya J, Kirenga B, Getahun H . Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin TB Mycobact Dis, 2016,3(3):10-12. |
[18] |
Connolly LE, Edelstein PH, Ramakrishnan L . Why is long-term therapy required to cure tuberculosis? PLoS Med, 2007,4(3):e120.
doi: 10.1371/journal.pmed.0040120 URL |
[19] |
丁晓艳, 许卫国, 竺丽梅 , 等. 175例耐多药肺结核患者治疗转归情况分析. 中国防痨杂志, 2014,36(4):238-243.
doi: 10.3969/j.issn.1000-6621.2014.04.003 URL |
[20] | 闫丽萍, 吴哲渊, 张祖荣 , 等. 初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究. 中国防痨杂志, 2017,39(1):33-38. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||